🇺🇸 FDA
Patent

US 6797276

Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response

expired A61KA61K2039/53A61K2039/54

Quick answer

US patent 6797276 (Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response) held by The United States of America as represented by the Secretary of the Army expires Mon Sep 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The United States of America as represented by the Secretary of the Army
Grant date
Tue Sep 28 2004 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K2039/53, A61K2039/54, A61K2039/55505, A61K2039/55511